{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myasthenia+Gravis+in+Children",
    "query": {
      "condition": "Myasthenia Gravis in Children"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T05:14:16.836Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05374590",
      "title": "Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis",
        "gMG"
      ],
      "interventions": [
        {
          "name": "Efgartigimod IV or Efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 12,
      "start_date": "2022-08-18",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-06-26T05:14:16.836Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Charlotte, North Carolina • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05374590"
    },
    {
      "nct_id": "NCT04833894",
      "title": "Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Efgartigimod IV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 12,
      "start_date": "2021-10-26",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-06-26T05:14:16.836Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Chapel Hill, North Carolina • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04833894"
    },
    {
      "nct_id": "NCT06392386",
      "title": "A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-06-28",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-26T05:14:16.836Z",
      "location_count": 3,
      "location_summary": "Charlotte, North Carolina • Denton, Texas • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Denton",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06392386"
    },
    {
      "nct_id": "NCT05265273",
      "title": "A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Nipocalimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 12,
      "start_date": "2022-07-20",
      "completion_date": "2029-07-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-06-26T05:14:16.836Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05265273"
    },
    {
      "nct_id": "NCT04031469",
      "title": "A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease",
      "overall_status": "SUSPENDED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gut Microbiome",
        "Gastrointestinal Microbiome",
        "Autism",
        "Autism Spectrum Disorder",
        "Autism Spectrum Disorder High-Functioning",
        "Alzheimer Disease",
        "Alzheimer Dementia (AD)",
        "Alzheimer Dementia",
        "Alzheimer Disease (AD)",
        "Crohn",
        "Crohn Colitis",
        "Crohn Disease (CD)",
        "Crohn Disease Colon",
        "Myalgic Encephalomyelitis",
        "ME/CFS",
        "Myalgic Encephalomyelitis (ME)",
        "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome",
        "Psoriasis",
        "Psoriasis Annularis",
        "Psoriasis Chronic",
        "Chronic Urinary Tract Infection",
        "Ulcerative Colitis (Disorder)",
        "Ulcerative Colitis (UC)",
        "Ulcerative Colitis Acute",
        "Ulcerative Colitis Chronic",
        "Multiple Sclerosis",
        "Multiple Sclerosis (MS) - Relapsing-remitting",
        "Multiple Sclerosis (MS) Primary Progressive",
        "Constipation Chronic Idiopathic",
        "Constipation",
        "Celiac",
        "Celiac Disease",
        "Celiac Sprue",
        "Lyme Arthritis",
        "Lyme Borreliosis, Nervous System",
        "Lyme Disease, Chronic",
        "Cholesterol",
        "Cholesterol Level, High",
        "Cancer",
        "Colon Cancer",
        "Amyotrophic Lateral Sclerosis (ALS)",
        "Amyotrophic Lateral Sclerosis",
        "Rheumatoid Arthritis (RA)",
        "Rheumatoid Arthritis - Rheumatism",
        "Chronic Fatigue Syndrome (CFS)",
        "PARKINSON DISEASE (Disorder)",
        "Parkinson Disease",
        "Parkinson Disease (PD)",
        "Depression",
        "Major Depressive Disorder (MDD)",
        "Depression Disorder",
        "Depression in Adults",
        "Anxiety",
        "Anxiety Disorder Generalized",
        "Obsessive Compulsive Disorder (OCD)",
        "Obsessive Compulsive Disorder OCD",
        "Obsessive - Compulsive Disorder",
        "Bipolar",
        "Bipolar 1 Disorder",
        "Bipolar Disorder (BD)",
        "Bipolar Disorder I and II",
        "Bipolar and Related Disorders",
        "Migraine",
        "Migraine Disorder",
        "Diabetes (DM)",
        "Diabetes",
        "Lupus",
        "Lupus Erythematosus",
        "Epidermolysis Bullosa (EB)",
        "Mesothelioma",
        "Mesothelioma Malignant",
        "IBS (Irritable Bowel Syndrome)",
        "Irritable Bowel",
        "IBS - Irritable Bowel Syndrome",
        "Irritable Bowel Syndrome (IBS)",
        "Eczema",
        "Eczema Atopic Dermatitis",
        "Acne",
        "Myasthaenia Gravis",
        "Gout"
      ],
      "interventions": [
        {
          "name": "There is no intervention in this study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ProgenaBiome",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2019-07-11",
      "completion_date": "2030-12-10",
      "has_results": false,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-06-26T05:14:16.836Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04031469"
    },
    {
      "nct_id": "NCT04806620",
      "title": "Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Post-Acute COVID-19 Syndrome",
        "ME/CFS",
        "Rheumatic Arthritis",
        "Juvenile Rheumatoid Arthritis (JRA)",
        "Psoriatic Arthritis (PsA)",
        "Ankylosing Spondylitis (AS)",
        "Autoimmune Encephalitis",
        "Celiac Disease",
        "Celiac Disease in Children",
        "Chronic Lyme Disease",
        "Post-treatment Lyme Disease Syndrome",
        "Crohn's Disease",
        "Dysautonomia",
        "Anorexia Nervosa",
        "Bulimia Nervosa",
        "ARFID",
        "Avoidant / Restrictive Food Intake Disorder",
        "Ehlers Danlos Syndrome",
        "Endometriosis",
        "Fibromyalgia (FM)",
        "Long COVID",
        "Lupus",
        "Migraines",
        "Mast Cell Activation Syndrome",
        "Multiple Sclerosis",
        "Myalgic Encephalomyelitis (ME)",
        "Myasthenia Gravis, Generalized",
        "Myasthenia Gravis in Children",
        "Narcolepsy",
        "Obsessive Compulsive Disorder (OCD)",
        "PANDAS",
        "Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)",
        "POTS - Postural Orthostatic Tachycardia Syndrome",
        "General Anxiety Disorder, Social Anxiety Disorder",
        "PTSD - Post Traumatic Stress Disorder",
        "Psoriasis",
        "Traumatic Brain Injury",
        "Tourette's Syndrome",
        "Inflammatory Bowel Disease (IBD)",
        "Autoimmune Diseases",
        "Neurological Diseases or Conditions",
        "Psychiatric Disorder",
        "Sjogren's Syndrome",
        "Ulcerative Colitis and Crohn's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Brain Inflammation Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 10000,
      "start_date": "2023-07-05",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-06-26T05:14:16.836Z",
      "location_count": 1,
      "location_summary": "Delafield, Wisconsin",
      "locations": [
        {
          "city": "Delafield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04806620"
    },
    {
      "nct_id": "NCT06987539",
      "title": "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Inebilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 15,
      "start_date": "2026-08-31",
      "completion_date": "2030-03-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-06-26T05:14:16.836Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06987539"
    }
  ]
}